Key result
Visceral Adiposity Index and Lipid Accumulation Product effectively predicted the presence of at least three cardiovascular risk factors in non-obese PCOS patients, with AUCs of 0.935 and 0.945.
Why the study?
Patients with PCOS have an increased risk of cardiovascular events closely related to increased visceral fat accumulation, prompting exploration of noninvasive adiposity markers VAI and LAP in non-obese patients.
Do Visceral Adiposity Index and Lipid Accumulation Product scores accurately predict cardiometabolic risk in non-obese women with PCOS?
Population
66 PCOS cases and 40 healthy controls aged 18-35
Comparison
PCOS cases vs healthy controls
Design
Case-control study
Authors
Loading...
May support VAI/LAP screening in non-obese PCOS; hypothesis-generating, requires prospective validation before practice change.
Case-Control (n=106)
Do Visceral Adiposity Index and Lipid Accumulation Product scores accurately predict cardiometabolic risk in non-obese women with PCOS?
Effect estimate: AUC 0.935 for VAI; AUC 0.945 for LAP
VAI and LAP are simple, noninvasive, and effective screening tools for assessing cardiometabolic risk in non-obese women with PCOS.
Bir et al. (2023) conducted a case-control in Non-obese polycystic ovary syndrome (PCOS) (n=106). Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) vs. Healthy controls was evaluated on Predictive power for the presence of at least three cardiovascular risk factors (AUC 0.935 for VAI; AUC 0.945 for LAP). Visceral Adiposity Index and Lipid Accumulation Product effectively predicted the presence of at least three cardiovascular risk factors in non-obese PCOS patients, with AUCs of 0.935 and 0.945.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: